<DOC>
	<DOCNO>NCT00440232</DOCNO>
	<brief_summary>We test hypothesis subject treatment group experience few fasting induce headache compare placebo group.In clinical experience , estimate approximately 25 % headache population experience fasting-induced migraine hunger-induced migraine . With give migraine incidence 28 million United States alone , estimate approximately 7 million experience hunger migraine trigger . If individual know migraine trigger , variety way modify care order address trigger . The simple avoid trigger preemptively treat trigger . Frovatriptan good evidence daily use short time help prevent menstrually related migraine . A short course treatment often avoid initiation migraine improve quality life . Knowing longer act triptan , frovatriptan , demonstrate capability suppress headache know trigger , suggest need study fast induced migraine , well .</brief_summary>
	<brief_title>A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Male female subject age 18 65 , inclusive Subjects diagnose episodic migraine , without aura accord IHS criterion least oneyear prior screen Subjects experience 1 6 migraine attack per month inclusive ( previous 6 month ) 15 day headache per month . Subject report hunger fast know trigger migraine Subject use agrees use duration participation medically acceptable form contraception ( determined investigator ) , female childbearing potential Subjects able understand comply study procedure . Subject willing complete one 20hour fast , start 5:00 8:00 P.M. , food drink ( except water need take routine medication ) Subject provide write informed consent prior screen procedure conduct If subject take preventive migraine medication migraine reason , medication must stable dose least 4 week prior screen , must remain stable throughout duration study . EXCLUSION CRITERIA Pregnant and/or lactate woman Subjects history clinically relevant allergy frovatriptan like compound Subjects , investigator opinion , history evidence medical psychiatric condition would expose increase risk significant adverse event would interfere assessment efficacy tolerability trial Subjects participate investigational drug trial 30 day prior screen visit Subjects currently history significant cerebrovascular disease include basilar hemiplegic migraine Subjects history nonresponse triptans , determine investigator Subjects uncontrolled hypertension Subjects diabetes mellitus require insulin oral antihyperglycemic agent exclude . ( Subjects Type II diabetes well control diet exercise alone may include . ) Subjects currently history ischemia and/or vasospastic coronary artery disease Subjects , investigator opinion , significant risk factor coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>